On November 14, 2024, Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced its financial results for the third quarter ending September 30, 2024. The company reported a cash balance of $18.5 million, a significant increase from $0.2 million at the end of 2023, extending its financial runway into 2026. Research and development expenses decreased to $1.0 million from $1.9 million in the same quarter of the previous year, while general and administrative expenses also saw a reduction. However, the company recorded a net loss of $12.2 million, primarily due to a $9.7 million non-cash intangible asset impairment charge. Allarity highlighted operational achievements including positive patient outcomes in the Phase 2 trial of stenoparib for advanced ovarian cancer, the appointment of new leadership, securing a European patent for its stenoparib DRP® companion diagnostic, and regaining NASDAQ compliance. The company's CEO, Thomas Jensen, expressed optimism for the future, particularly for stenoparib's potential to offer new hope to ovarian cancer patients with limited treatment options.

On November 14, 2024, Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced its financial results for the third quarter ending September 30, 2024. The company reported a cash balance of $18.5 million, a significant increase from $0.2 million at the end of 2023, extending its financial runway into 2026. Research and development expenses decreased to $1.0 million from $1.9 million in the same quarter of the previous year, while general and administrative expenses also saw a reduction. However, the company recorded a net loss of $12.2 million, primarily due to a $9.7 million non-cash intangible asset impairment charge. Allarity highlighted operational achievements including positive patient outcomes in the Phase 2 trial of stenoparib for advanced ovarian cancer, the appointment of new leadership, securing a European patent for its stenoparib DRP® companion diagnostic, and regaining NASDAQ compliance. The company's CEO, Thomas Jensen, expressed optimism for the future, particularly for stenoparib's potential to offer new hope to ovarian cancer patients with limited treatment options.